Nemes Rush Group’s Acadia Pharmaceuticals ACAD Stock Holding History

Nemes Rush Group’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$50.6K	Hold	2,000	–	–	﹤0.01%	373
2026 Q1	$44.5K	Hold	2,000	–	–	﹤0.01%	371
2025 Q4	$53.4K	Hold	2,000	–	–	0.01%	339
2025 Q3	$42.7K	Hold	2,000	–	–	﹤0.01%	346
2025 Q2	$43.1K	Hold	2,000	–	–	﹤0.01%	349
2025 Q1	$33.2K	Hold	2,000	–	–	﹤0.01%	361
2024 Q4	$36.7K	Hold	2,000	–	–	﹤0.01%	339
2024 Q3	$37K	Hold	2,000	–	–	0.01%	295
2024 Q2	$32.5K	Hold	2,000	–	–	﹤0.01%	303
2024 Q1	$37K	Hold	2,000	–	–	0.01%	320
2023 Q4	$62.6K	Hold	2,000	–	–	0.01%	243
2023 Q3	$41.7K	Hold	2,000	–	–	0.01%	272
2023 Q2	$47.9K	Buy	+2,000	New	+$44.5K	0.01%	268

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Nemes Rush Group's ACAD Position: Q2 2026 in Review

Nemes Rush Group held its Acadia Pharmaceuticals (ACAD) position steady in Q2 2026 at 2,000 shares worth $50.6K. The position accounts for ﹤0.01% of the portfolio, ranked #373.

Nemes Rush Group first reported a position in ACAD in Q2 2023 and has held it in 13 quarters since. The position peaked at $62.6K in Q4 2023. 353 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

Nemes Rush Group held 2,000 shares of Acadia Pharmaceuticals worth $50.6K as of Q2 2026.
Nemes Rush Group left its Acadia Pharmaceuticals share count unchanged in Q2 2026.
Acadia Pharmaceuticals made up ﹤0.01% of Nemes Rush Group's portfolio in Q2 2026, its #373 holding.
Nemes Rush Group first reported a position in Acadia Pharmaceuticals in Q2 2023 and has held it in 13 quarters since.
Nemes Rush Group's Acadia Pharmaceuticals position peaked at $62.6K in Q4 2023.
353 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Nemes Rush Group's 13F filing for Q2 2026, filed 14 Aug 2026.